Qilu Pharmaceutical
As of the edition of 20 October 2026, Qilu Pharmaceutical runs 69 drugs; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Active | 46 |
| Went quiet | 2 |
| Stopped | 1 |
| Status not established | 20 |
| Total | 69 |
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Qilu Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 57 trials led
- Immune system: 18 trials led
- Lungs and airways: 18 trials led